



		EMLc	ATC codes: V03AF01
Indication	Ewing sarcoma of bone and articular cartilage of unspecified sites		
	ICD11 code: 2C22.Z		
INN	Mesna		
Medicine type	Chemical agent		
List type	Complementary (EML) (EMLc)		
Formulations	Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule ; 100 mg per mL in 10 mL ampoule Oral > Solid: 400 mg ; 600 mg		
EML status history	First added in 2015 (TRS 994)		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> .		
Tags	<a href="#">Cancer</a> <a href="#">Cancer supportive care</a>		
Wikipedia	<a href="#">Mesna</a>		
DrugBank	<a href="#">Mesna (Coenzyme M)</a>		

### Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for mesna on the complementary list of the EML and EMLc for use in treatment protocols for Ewing sarcoma was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for Ewing sarcoma is attached.

[Expert Committee report](#) 